Joshua Lehrer-Graiwer
Nessuna posizione attualmente
Patrimonio netto: 3 M $ in data 30/04/2024
Profilo
Joshua Lehrer-Graiwer formerly worked at Graphite Bio, Inc., as President, CEO, CFO, CAO & Director in 2023 and Global Blood Therapeutics, Inc., as Chief Medical Officer from 2019 to 2020.
Dr. Lehrer-Graiwer received his undergraduate degree from Harvard University, graduate degree from the University of Cambridge, and doctorate degree from The University of California, San Francisco.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
0.65% | 01/02/2024 | 165 953 ( 0.65% ) | 3 M $ | 30/04/2024 |
Precedenti posizioni note di Joshua Lehrer-Graiwer
| Società | Posizione | Fine |
|---|---|---|
| LENZ THERAPEUTICS, INC. | Amministratore Delegato | 21/08/2023 |
| GLOBAL BLOOD THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 17/04/2020 |
Formazione di Joshua Lehrer-Graiwer
| University of Cambridge | Graduate Degree |
| Harvard University | Undergraduate Degree |
| The University of California, San Francisco | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 2 |
|---|---|
Global Blood Therapeutics, Inc.
 Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |
Graphite Bio, Inc.
 Graphite Bio, Inc. BiotechnologyHealth Technology Graphite Bio, Inc. is a clinical-stage gene editing company. It engages in the business of developing therapies that harness targeted gene integration to treat or cure serious diseases. The company was founded by Matthew Porteus and Maria Grazia Roncarolo on June 1, 2017 and is headquartered in South San Francisco, CA. | Health Technology |
- Borsa valori
- Insiders
- Joshua Lehrer-Graiwer